How a pharma company made billions off mass murder by faking the science on Oxycontin

When Purdue Pharma's patent on the MS Contin was close to expiry, the Sackler family who owned the company spent millions trying to find a product that could replace the profits they'd lose from generic competition on MS Contin: the result was Oxycontin, a drug that went on to kill Americans at epidemic scale. Read the rest

This man's medication cost jumped from $400 a month to $40,000 a month

Neven Mrgan takes a prescription drug called Cuprimine. Without it, he would slowly die from liver disease. Unfortunately, the price of Cuprimine has gone from $400-$1,700/month to $44,000/month. Curprimine is made by Valeant Pharmaceuticals, run by billionaire J. Michael Pearson. He's stepping down, not because he jacked up the price of Cuprimine and other medications, but because the company's misstated earnings hurt its stock value.

Read the rest

Doctors who get pharma money prescribe brand-name drugs instead of generics

It's an open secret that the pharmaceutical industry spends billions marketing to doctors, deliberately misleading them about their products, raking in record profits that they shift into offshore tax-havens through legally questionable means, while lobbying for global treaties that benefit them at the expense of the sick. Read the rest

Profile of James Love, "Big Pharma's worst nightmare"

Jamie Love is one of the founders of Knowledge Ecology International (formerly the Consumer Project on Technology), a super-effective activist NGO that helped to establish low-cost, global access to HIV/AIDS drugs. Read the rest

Martin Shkreli is right: fraud charges only arose because of pharma scumbaggery

Martin Shkreli, the notorious, most-hated-man-on-the-Internet pharma douchebro who was arrested last week for securities fraud, told the FBI that the only reason they bothered busting him for financial corruption is that he had made a spectacle out of himself with his pharma shenanigans. Read the rest

Experts baffled to learn that 2 years olds are being prescribed psychiatric drugs

In 2014, US doctors wrote ~20,000 prescriptions for risperidone, quetiapine and other antipsychotics for children under the age of two; a cohort on whom these drugs have never been tested and for whom there is no on-label usage. Read the rest

Pharma-hedge-douche: I should've charged more for AIDS/cancer drug

Martin Shkreli, the most hated man on the Internet, regrets that he jacked up the price of the off-patent drug Daraprim, taken mainly by people with AIDS and cancer, by a mere 5,000%. Read the rest

AIDS-drug-gouging hedge-douche reneges on promise to cut prices for Daraprim

Martin Shkreli, the hedge-fund douche-bro who hiked the price of an off-patent drug used by AIDS and cancer patients from $13.50 to $750, then promised to lower the prices after becoming the Most Hated Man on the Internet did no such thing, because he is a liar. Read the rest

Pharma company offers $1/dose version of hedge-fund douchenozzle's drug

Former hedge-fund manager Martin Shkreli became a poster child for greed and sleaze when he bought the only company that was tooled up to make an off-patent drug called Daraprim that people with HIV used to control parasitic toxoplasmosis infections and jacked the price from $13.50 per tablet to $750 per tablet. Read the rest

When scientists hoard data, no one can tell what works

Peer review and replication are critical to the scientific method, but in medical trials, a combination of pharma company intransigence and scientists' fear of being pilloried for human error means that the raw data that we base life-or-death decisions upon is routinely withheld, meaning that the errors lurk undetected in the data for years -- and sometimes forever. Read the rest

Spectacular, weird horror movie as pharma infomercial

Adult Swim's Unedited Footage of a Bear trumps Too Many Cooks for intensity, virtuosity and genuine terror. Read the rest

Brian Krebs's "Spam Nation"

In Spam Nation: The Inside Story of Organized Cybercrime-from Global Epidemic to Your Front Door, Brian Krebs offers a fascinating look at the mass-scale cybercrime that underpins the spam in your inbox and provides an inside peek at a violent fight among its principle players. Cory Doctorow reviews.

Canada's anti-counterfeiting bill stalled by US demand for removal of humanitarian safeguards

Michael Geist writes, "Last year, the Canadian government trumpeted anti-counterfeiting legislation as a key priority. The bill raced through the legislative process in the winter and following some minor modifications after committee hearings, seemed set to pass through the House of Commons. Yet after committee approval, the bill suddenly stalled with little movement throughout the spring. Why did a legislative priority with all-party approval seemingly grind to a halt?" Read the rest

Back pain: Acetaminophen no better than placebos

A large-scale, rigorous study published in the Lancet found that the go-to, front-line treatment for back pain was no better than a placebo. Read the rest

As kids' accidental ODs rise, FDA still won't mandate flow restrictors in medicine bottles

In America, more under-6 kids go to the emergency room from accidental overdose than from car-accidents -- they get hold of medicine and drink the whole bottle. Since 2007, epidemiologist Dr Daniel Budnitz has campaigned for the use of flow-restrictors in children's medicine bottles, which dramatically reduce the likelihood of an OD; manufacturers started adding restrictors to acetaminophen in 2011, but stopped there.

Flow restrictors have not been added to bottles of antihistamines, ibuprofen, and cough and cold preparations -- even where they contain the same concentration of acetaminophen as plain acetaminophen tinctures. These other medicines account for about half of all overdoses by small children.

In a long, investigative piece, Pro Publica and Consumer Reports exhaustively document the effectiveness of restrictors, the intransigence of bottom-line-focused pharmaceutical manufacturers, and the real risks of children's medicine overdoses.

An FDA mandate would solve the problem of liquid overdose at the stroke of a pen, but the FDA refuses, preferring a voluntary approach that is demonstrably not working -- and putting kids at risk. The incidence of overdose in small children is not only widespread -- it's rising. Flow-restrictors are cheap, effective low-hanging fruit. Restrictors were invented to improve dosing and reduce spills in adult medicine, and are thus of benefit to everyone, not just parents. Read the rest

Retinol is a magical skin potion

Anyone who tries to google skincare products hits a brick wall of fake reviews, SEO spam and hysterical pseudoscientific terror. Vogue's Christina Mueller writes that the blind-studied, peer-reviewed answer to your question is probably "Retinol":

Imagine for a moment that a revolutionary skin-care ingredient was discovered. It visibly smoothed out wrinkles and obliterated breakouts; it improved skin texture and tightened pores into tiny little nothings. ... Such an ingredient does exist, and chances are some form of it is currently languishing in a corner of your medicine cabinet. It’s retinol. It isn’t sexy. It definitely isn’t new. In fact, it was discovered 81 years ago, making it a veritable dowager compared with all the fresh new super-ingredients that have since come onto the anti-aging scene. For the past few decades, it has been hiding in plain sight—but with a few new developments, it is stepping back into the limelight.
Read the rest

Public interest groups fly to Auckland, NZ to meet with TPP negotiators, are only allowed in the building to give a 15-minute joint presentation

Having been promised a chance to meet with the delegates at the secretive Trans Pacific Partnership treaty meeting in New Zealand, a representatives from nonprofit public interest groups around the world flew to Auckland. Once they arrived, the TPP announced that they would be granted 15 minutes, total, for all of the groups to make a statement.

TPP is a sweeping copyright treaty, a kind of ACTA on steroids, being conducted without any public scrutiny or input -- only governments and giant corporations are welcome in the negotiating room. It has profound implications for the future of medicine, Internet regulation, and privacy and surveillance.

The Electronic Frontier Foundation is one of the groups that sent a representative to Auckland. They've published an open letter signed by the public interest coalition protesting their shabby treatment at the hands of TPP's administrators.

Academics, experts, consumer groups, Internet freedom organizations, libraries, educational institutions, patients and access to medicines groups have flown a long way from around the world to Auckland, New Zealand, to engage with delegates in the 15th round of Trans-Pacific Partnership negotiations.

For the first time, however, we have been locked out of the entire venue, except for a single day out of the 10 days of negotiations. This not only alienates us as members of public interest groups, but also the hundreds of thousands of innovators, educators, patients, students, and Internet users who have sent messages to government representatives expressing their concerns with the TPP. All of us oppose the complete unjustifiable secrecy around the negotiations, but more importantly, the IP provisions that could potentially threaten our rights, and innovation.

Read the rest

More posts